Schering-Plough's second-quarter profit falls despite sales increase
This article was originally published in Scrip
Schering-Plough's second-quarter pharmaceutical net sales were up by 47% to $3.7 billion, though group income was down by 19% to $436 million due largely to charges that the company incurred upon the cancellation of its development programme with Merck & Coon a Claritin/Singulair combination (Scrip Online, June 30th, 2008). Total group sales were up by 55% to $4.9 billion.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.